Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23368384 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL7362337 | 0.81 | AKR1A1 (0.47) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL25084322 | 0.81 | IDO1 (0.52) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL18549620 | 0.77 | IDO1 (0.49) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL17023688 | 0.77 | CFD (0.49) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL29781757 | 0.77 | CFD (0.49) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL443715 | 0.74 | KRAS (0.59) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL24114228 | 0.72 | PTGDR2 (0.44) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL25370049 | 0.72 | AKR1A1 (0.45) | SMN1; SMN2AKR1A1AKR1B1ALDH1A1PTGDR2 | |
| SCHEMBL411220 | 0.72 | KDM4E (0.56) | SMN1; SMN2AKR1A1AKR1B1PTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | SMN1; SMN2 4499/4885AKR1A1 3043/4885AKR1B1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.